期刊
ATHEROSCLEROSIS
卷 263, 期 -, 页码 92-96出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2017.06.009
关键词
Tendon xanthomas; Familial hypercholesterolemia; PCSK9; Alirocumab; Evolocumab
资金
- Instituto de Salud Carlos III [PI15/01983, PIE16/00022]
- CIBERCV [IIS16/0114]
Background and aims: The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown. Methods: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year. Results: Exposure to PCSK9 inhibitors in cases was 2.96 +/- 1.33 years. LDLc decreased 80.8 +/- 7.66% in cases and 56.9 +/- 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction. Conclusion: Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据